BVS vs VCYT: fair value comparison
Bioventus Inc. and Veracyte, Inc. · Updated 2026-10-19
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, VCYT currently sits closer to the top of our ranking by discount to fair value. VCYT carries the stronger quality grade.
| BVS | VCYT | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $13.30 | $43.12 |
| 12-month range | $6.53–$15.26 | $30.01–$60.49 |
| Rank by discount to fair value | #67 of 108 Healthcare | #65 of 108 Healthcare |
| Quality grade | B | A |
| Leverage | Moderate | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: BVS fair value analysis · VCYT fair value analysis